Burda Principal Investments joins €240M investment round in AMBOSS to support global expansion
Burda Principal Investments (BPI) is excited to announce our investment in AMBOSS, the leading medical education platform and digital co-pilot for physicians. This participation in the company’s €240 million financing round marks BPI’s second investment under our newly defined later growth strategy, following Nord Security.
“We have always captured the entire range of growth capital. We recently implemented two separate investment strategies for early growth and later growth capital, which help us be more agile. Nord Security and AMBOSS are two great examples of this,” explains Christian Teichmann, CEO of Burda Principal Investments.
Supporting Medical Professionals with AI-Powered Knowledge
Founded in Berlin, AMBOSS has established itself as a trusted platform for over one million medical professionals and students in more than 180 countries. Originally launched as an exam preparation tool, the company has since evolved into an essential resource for both individuals and institutions, including universities, hospitals, and healthcare systems. By integrating structured medical knowledge with interactive features, AMBOSS enables healthcare professionals to make informed decisions quickly and effectively.
The company addresses two fundamental needs in healthcare: supporting lifelong education and professional development, as well as offering real-time decision support by providing quick, evidence-based medical insights at the point of care.
AMBOSS is trusted by over one million users in more than 180 countries for clinical decision-making and medical education. In Germany, half of all inpatient treatments are carried out by physicians supported by AMBOSS. In the U.S., the majority of medical students use the platform to prepare for exams, achieving higher scores than with other question banks. Additionally, 25% of first-year residents in the U.S. rely on AMBOSS to provide exceptional patient care. The platform’s success lies in its straightforward yet highly effective approach: medical experts distill essential knowledge, which is then delivered directly to users through AI-supported technology.
Investing in a High-Growth Company
“As global healthcare systems are increasingly challenged, and the level of patient care declines due to an aging population, workforce shortage, and overall rising costs, AMBOSS is not only building a fantastic company but a critical technology solution: digitally empowering physicians, ensuring they remain at the centre of care and deliver the highest quality treatment.” Julian von Eckartsberg, BPI’s Managing Director Europe.
“AMBOSS continues to successfully revolutionise medical education and clinical decision-making. With its unwavering commitment to empowering healthcare professionals, AMBOSS is well-positioned to shape the future of global medical knowledge. We are thrilled to become a long-term partner to Benedikt, Madjid, Nawid, and the AMBOSS team.” Friedrich von Wulffen, Investment Principal at BPI.
AMBOSS is well positioned to expand further into the broader physician segment, new healthcare verticals, and additional global markets, including India and Brazil. By combining trusted medical content with AI-supported technology, the platform enables healthcare professionals to access reliable, real-time insights – enhancing medical education and improving patient care worldwide.
Strong Backing for Continued Growth
The €240 million investment round was led by KIRKBI, with participation from new investors M&G, Lightrock, Maj Invest, and Project A, alongside existing investors Partech, Cherry, Quadrille, and Wellington Partners. The funding will enable AMBOSS to accelerate its expansion, further develop its technology, and explore additional market opportunities.
With its scalable, subscription-based model and strong market position, AMBOSS is set to continue transforming medical education and clinical decision-making. At Burda Principal Investments, we are excited to support AMBOSS in its mission, and we look forward to being part of their continued success and innovation in healthcare.
Read more about AMBOSS here.
